Time to Treatment Initiation and Patient Characteristics in Newly Diagnosed Multiple Myeloma Patients With and Without Transplant: Real-World Evidence Using Big Data From England

Speaker(s)

Mary Babu E1, Pawlyn C2, Broe A3, Lay-Flurrie S3, Matsakidis P4, Fermahan S5, Bowen J5
1Sanofi, Reading, RDG, UK, 2The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, Greater London, UK, 3IQVIA Ltd, London, Greater London, UK, 4IQVIA, Porto Salvo, Lisbon, Portugal, 5Sanofi, Reading, UK

Presentation Documents

OBJECTIVES: Despite being a rare disease, multiple myeloma (MM) is the second most common haematologic malignancy in the UK. However, there is paucity of evidence on the rapidly evolving treatment landscape and outcomes in the real-world clinical setting. The purpose of this study was to understand the characteristics and routine treatment patterns of patients with MM in England.

METHODS: This was a retrospective cohort study of adult patients newly diagnosed with MM in England between 1 January 2014 to 31 August 2021, identified using the Cancer Analysis System (CAS, an individual level, population-wide database). Treatment progression and line of therapy (LoT) were derived algorithmically using Systemic anti-cancer therapy (SACT) data recorded between 1 January 2014 to 31 May 2022. Stem cell transplant (SCT) status (recorded vs. not recorded during follow-up) was determined from linked Hospital Episode Statistics data until 31 March 2021.

RESULTS: In total, 24,329 newly diagnosed patients were included. Based on technical exclusion criteria applied, 19,847 patients were included in the time to treatment initiation analysis. Approximately 26% of these patients began 1st line treatment within one month of diagnosis, while 51% took longer than 6 months to begin treatment (median time to treatment initiation: 6.4 months [95% CI: 5.9 to 6.9]). 12,095 patients had valid SACT records for analysis of transplant rates. Of these, 3,419 (28.3%) received an SCT during follow-up. Compared to those who did not receive an SCT, these patients were generally younger (median age at 1st LoT of 61.0 vs. 76.0 years) and had longer follow-up (median follow-up from start of 1st LoT of 40.0 vs. 22.2 months).

CONCLUSIONS: Findings from this study broadly align with published UK literature but also provide an updated snapshot of RWE pertaining to patients with MM in England.

Code

RWD160

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Clinician Reported Outcomes, Registries

Disease

Oncology